Assignee
ASCENDIS PHARMA ONCOLOGY DIV A/S
DK·3 granted patents·8 pending applications·2 citations·filing 2019–2022
Top patents by PatentIndex Score
11 records- 0186US11879001B2Conjugate comprising an IL-2 moietyASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2022·Granted Jan 23, 2024·2 cites·30 claims
- 0257US12428461B2Treating cancer with a conjugate comprising an IL-2 moietyASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2021·Granted Sep 30, 2025·0 cites·26 claims
- 0351US2023340055A1Glycosylated il-2 proteins and uses thereofASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2021·Application pending·0 cites
- 0448US12565525B2IL-2 conjugatesASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2019·Granted Mar 3, 2026·0 cites·23 claims
- 0545US2022054476A1Sustained local drug levels for innate immune agonistsASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
- 0645US2022054478A1Minimization of systemic inflammationASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
- 0745US2022054477A1Induction of sustained local inflammationASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
- 0845US2023102309A1Tyrosine kinase inhibitor conjugatesASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
- 0944US2025032638A1Novel Cancer Treatments with TLR7/8 AgonistsASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2022·Application pending·0 cites
- 1042US2022062273A1Conjugates of pattern recognition receptor agonistsASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
- 1140US2022305136A1Anti-ctla4 conjugatesASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ASCENDIS PHARMA ONCOLOGY DIV A/S files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →